Q-omics provides the consensus-scored TFDP2 profile across patient tissues and cancer cell-line models. TFDP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TFDP2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TFDP2 RNA expression shows 19,985 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, KIRC, and ACC as cancer lineages where TFDP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFDP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFDP2 survival associations across molecular data types. TFDP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFDP2 RNA expression–survival associations across cancer types. High TFDP2 expression shows unfavorable associations in LIHC and ACC, but favorable associations in READ, UCS, UVM and KIRC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for TFDP2 RNA expression.
This table summarizes TFDP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TFDP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFDP2 shows lower tumor expression in KIRC, KICH, THCA and BRCA and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher TFDP2 RNA expression in normal versus tumor tissue (log2 FC = −0.757, t-test p < 0.001).
This table shows molecular features associated with TFDP2 in patient tissues and cancer cell lines. In patient samples, TFDP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TFDP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
